Supplementary Table 1. Stratified analysis of the association between rs462779 in REV3L gene and platinum-based chemotherapy prognosis (n=348)

| Subgroups                        | Overall survival (OS) | Progression-free survival (PFS) |
|----------------------------------|-----------------------|---------------------------------|
|                                  | Death/Total           | HR (95% CI) P                    | Progression/total | HR (95% CI) P |
|                                  | TT        | TC/CC  | P     | TT        | TC/CC  | P     |
| Age (years)                      |           |        |       |           |        |       |
| ≤56                              | 36/42     | 87/129 | 0.61 (0.42-0.91) 0.015 | 38/42     | 101/129 | 0.83 (0.57-1.21) 0.328 |
| >56                              | 28/31     | 103/146| 0.75 (0.49-1.15) 0.188 | 29/31     | 108/146 | 0.72 (0.47-1.10) 0.128 |
| Gender                           |           |        |       |           |        |       |
| Female                           | 15/17     | 40/61  | 0.74 (0.39-1.41) 0.355 | 15/17     | 46/61  | 0.86 (0.47-1.58) 0.624 |
| Male                             | 49/56     | 150/214| 0.69 (0.50-0.96) 0.027 | 52/56     | 163/214| 0.77 (0.56-1.06) 0.115 |
| Smoking status                   |           |        |       |           |        |       |
| Never smoker                     | 27/32     | 74/111 | 0.70 (0.44-1.09) 0.116 | 29/32     | 85/111 | 0.75 (0.49-1.16) 0.196 |
| Ever smoker                      | 37/41     | 116/164| 0.65 (0.45-0.95) 0.026 | 38/41     | 124/164| 0.80 (0.55-1.15) 0.229 |
| Family history of cancer         |           |        |       |           |        |       |
| No                               | 61/70     | 181/262| 0.68 (0.51-0.92) 0.011 | 64/70     | 199/262| 0.78 (0.59-1.04) 0.085 |
| Yes                              | 3/3       | 9/13   | 0.53 (0.09-3.15) 0.485 | 3/3       | 10/13  | 0.85 (0.17-4.12) 0.835 |
| Histology                        |           |        |       |           |        |       |
| LUAD                             | 39/43     | 98/136 | 0.65 (0.45-0.94) 0.023 | 40/43     | 110/136| 0.82 (0.57-1.18) 0.276 |
| LUSC                             | 20/24     | 78/118 | 0.80 (0.49-1.33) 0.395 | 21/24     | 83/118 | 0.85 (0.52-1.39) 0.517 |
| Othersa                          | 5/6       | 14/21  | 1.14 (0.29-4.46) 0.848 | 6/6       | 16/21  | 0.56 (0.17-1.77) 0.320 |
| TNM stage                        |           |        |       |           |        |       |
| I / II                           | 3/4       | 4/6    | 0.53 (0.10-2.81) 0.454 | 4/4       | 4/6    | 0.09 (0.01-1.00) 0.050 |
| III / IV                         | 61/69     | 186/269| 0.68 (0.51-0.91) 0.009 | 63/69     | 205/269| 0.80 (0.60-1.07) 0.134 |
| Eastern Cooperative Oncology Group Performance Status |           |        |       |           |        |       |
| 0-1                              | 58/67     | 178/260| 0.67 (0.49-0.90) 0.008 | 61/67     | 197/260| 0.75 (0.56-1.01) 0.055 |
| >1                               | 6/6       | 12/15  | 0.48 (0.16-1.44) 0.192 | 6/6       | 12/15  | 1.36 (0.41-4.58) 0.617 |

HR, hazard ratio; CI, confidence interval; P, P-value for multivariate Cox hazards regression analysis with adjustment for age, gender, and histology; Ref., reference; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. P < 0.05 are indicated in bold text.

aOther carcinomas include adenosquamous carcinoma, large cell carcinoma, bronchogenic lung cancer, and mucoepidermoid carcinoma.
Supplementary Table 2. Stratified analysis of the association between rs1045411 in HMGB1 gene and platinum-based chemotherapy prognosis (n=348)

| Subgroups             | Overall survival (OS) | Progression-free survival (PFS) |
|-----------------------|-----------------------|---------------------------------|
|                       | Death/Total           | HR (95% CI) P                   | Progression/total | HR (95% CI) P |
|                       | AA   | AG/GG | P   | AA | AG/GG | P   |
| Age (years)           |                  |                                |                  |               |
| ≤56                   | 10/10 | 113/161 | 0.54 (0.28-1.04) | 0.064 | 10/10 | 129/161 | 0.82 (0.43-1.56) | 0.540 |
| >56                   | 8/8   | 123/169 | 0.68 (0.33-1.41) | 0.300 | 8/8   | 129/169 | 0.84 (0.41-1.73) | 0.639 |
| Gender                |                  |                                |                  |               |
| Female                | 6/6   | 49/72  | 0.58 (0.24-1.37) | 0.214 | 6/6   | 55/72  | 0.90 (0.38-2.13) | 0.818 |
| Male                  | 12/12 | 187/258 | 0.64 (0.35-1.15) | 0.135 | 12/12 | 203/258 | 0.84 (0.47-1.52) | 0.572 |
| Smoking status        |                  |                                |                  |               |
| Never smoker          | 8/8   | 93/135 | 0.50 (0.24-1.04) | 0.062 | 8/8   | 106/135 | 0.82 (0.40-1.69) | 0.588 |
| Ever smoker           | 10/10 | 143/195 | 0.75 (0.37-1.52) | 0.422 | 10/10 | 152/195 | 0.91 (0.45-1.81) | 0.779 |
| Family history of cancer |            |                                |                  |               |
| No                    | 17/17 | 225/315 | 0.63 (0.39-1.04) | 0.071 | 17/17 | 246/315 | 0.85 (0.52-1.39) | 0.516 |
| Yes                   | 1/1   | 11/15  | 0.15 (0.01-1.93) | 0.145 | 1/1   | 12/15  | 0.33 (0.03-3.42) | 0.354 |
| Histology             |                  |                                |                  |               |
| LUAD                  | 11/11 | 126/168 | 0.63 (0.34-1.18) | 0.147 | 11/11 | 139/168 | 0.96 (0.52-1.78) | 0.896 |
| LUSC                  | 6/6   | 92/136 | 0.69 (0.30-1.59) | 0.381 | 6/6   | 98/136 | 0.73 (0.32-1.69) | 0.462 |
| Othersa               | 1/1   | 18/26  | ns          | 1.000 | 1/1   | 21/26  | 0.25 (0.02-2.90) | 0.265 |
| TNM stage             |                  |                                |                  |               |
| I / II                | 0/0   | 7/10   | NA          | NA   | 0/0   | 8/10   | NA          | NA |
| III / IV              | 18/18 | 229/320 | 0.62 (0.38-1.00) | 0.050 | 18/18 | 250/320 | 0.84 (0.52-1.36) | 0.484 |
| Eastern Cooperative Oncology Group Performance Status | | | | | |
| 0-1                   | 17/17 | 219/310 | 0.57 (0.35-0.93) | 0.025 | 17/17 | 241/310 | 0.77 (0.47-1.27) | 0.309 |
| >1                    | 1/1   | 17/20  | 0.63 (0.05-7.61) | 0.713 | 1/1   | 17/20  | 0.47 (0.04-6.00) | 0.559 |

HR, hazard ratio; CI, confidence interval; P, P-value for multivariate Cox hazards regression analysis with adjustment for age, gender, and histology; Ref., reference; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. P ≤ 0.05 are indicated in bold text.

*aOther carcinomas include adenosquamous carcinoma, large cell carcinoma, bronchogenic lung cancer, and mucoepidermoid carcinoma.